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Anti-Tumor Effect of Doxycycline on Glioblastoma Cells
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Zhou1
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Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA [E. Siegel; L.
F. Hutchins]; Department of Neuroscience, University of Cincinnati, Cincinnati, OH, USA [D. A. Mayes]; Department
of Neurological Surgery, University of California, Irvine, CA, USA [Y.-H. Zhou]
AIM: Glioblastoma multiforme (GBM) is the most common primary brain tumor in
humans, and it is highly invasive.  Doxycycline, first identified as an antimicrobial
agent, is a nonspecific inhibitor of matrix metalloproteinases (MMPs).  Our objective
was to investigate the anti-MMP effect of doxycycline at therapeutically acceptable
levels on glioma cells in vitro.
METHODS: The MTT assay was used to determine the anti-proliferative effects of
doxycycline.  MMP2 activity and expression were determined by gelatinase zymo-
graphy and real-time quantitative RT-PCR, respectively.  Cell invasion was assessed
by Matrigel invasion assay.
RESULTS: Doxycycline exerted mild anti-proliferative effects on all three glioma cell
lines (U251HF, U87 and LN229).  In U251HF cells, doxycycline decreased extracellular
MMP2 activity and reduced cell invasiveness.  Moreover, MMP2 mRNA levels were not
altered, suggesting that doxycycline regulates MMP2 activity post-translationally.
Alternatively, doxycycline increased the expression and extracellular activity of MMP2
in U87 cells.  This may reflect the cellular stress-response related to the cytotoxic
effects experienced by U87 cells in response to doxycycline exposure.
CONCLUSION: Doxycycline in therapeutic concentrations decreases MMP2 activity
and cell invasion in the most aggressive cell line tested, suggesting its potential as a
therapeutic MMP inhibitor.  The cytotoxic effects of doxycycline, however, can
enhance MMP2 expression, and this deserves further exploration.







Glioblastoma multiforme (GBM2) is the most common type
of primary brain tumor, with 8,000 to 10,000 cases diagnosed
each year in North America.  Over the last two decades, GBM
has remained one of most malignant cancers.  Patients with
GBM have a very poor prognosis, with a median survival of
∼14 months after surgical resection, chemotherapy and
radiation [1].  One of the challenges in the treatment of GBM
is the frequency of recurrences.  Recurrences often occur
adjacent to the resection site, suggesting the presence of
residual malignant glioma cells after tumor removal [2].  This
clinical phenomenon reflects the aggressive and infiltrative
behavior of malignant glioma cells.
Matrix metalloproteinases (MMPs) are an important family
of zinc endopeptidases whose members degrade extra-
cellular matrix, providing a space into which cells can
migrate [3].   In addition, MMPs can cleave other growth fact-
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ors and activate signal transduction cascades to promote
cell motility and proliferation [4].  Specifically, MMP2 and
MMP9 play a pivotal role in enhancing glioma tumor
migration, invasion, and angiogenesis [5].  Moreover,
increased MMP2 and MMP9 expression in gliomas is
associated with poor clinical outcomes [4], and inhibiting
these proteinases dramatically reduces the invasiveness of
glioma cells in vitro and in vivo [6].  Therefore, MMP
inhibitors are potential candidates to block glioma migration
and invasion in vivo.
The efficacy of an MMP inhibitor (marimastat) together
with an alkylator (temozolomide, TMZ) was previously tested
in a phase-II clinical trial in recurrent GBM patients.  The
combination treatment resulted in a progression-free
survival at 6 months that exceeded the literature target by
29% [7].  However, large randomized trials have not been
conducted because of multiple factors such as poor oral
tolerability, high incidences of musculolskeletal adverse
effects with marimastat, and an overall disappointing
performance of MMP inhibitors in clinical trials studying
other solid tumor types.  Therefore, there is a need to
explore the efficacy of alternative MMP inhibitors that may
have less adverse effects in vivo.  Doxycycline is one such
candidate [8].
Doxycycline is an antimicrobial agent, and has been
widely used in treating malaria, anthrax, tick-born diseases
and other bacterial infections [9].  No major toxicity has been
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reported with long-term use, and doxycycline exhibits a
variety of anti-tumor properties, such as inhibition of
mitochondrial protein synthesis [10,11], anti-invasion effects
via inhibition of MMPs [12-14], and anti-angiogenesis effects
[15].  It works as a non-specific MMP inhibitor in a variety of
tumor cell lines, including breast, colon, mesothelioma,
osteosarcoma, renal, prostate, and melanoma [13,14,16-20].
Although the mechanism of MMP inhibition is not entirely
clear, chelation of a zinc ion by doxycycline at the active site
of the enzyme has been reported [21].  This MMP inhibition
by doxycycline can occur within the normal therapeutic dose
range (less than 10 µg/ml)[22,23], which makes it a very
attractive agent for further examination as a potential
therapy targeting tumor migration and invasion [24].
To investigate the potential of doxycycline as a
therapeutic agent for GBM, we determined its effects on
GBM cell growth in three GBM cell lines and observed its
effects on MMP2 activity and invasion capacity in vitro.  Our
data showed that doxycycline, either as a cytotoxic agent or
an MMP inhibitor, is a reasonable candidate to further
explore as a pharmaceutical intervention for GBM.
Materials and Methods
Chemical reagent
Doxycycline was purchased from Sigma-Aldrich (St Louis,
MO, USA) and dissolved in PBS to prepare a stock solution
of 10 mg/ml.  The stock solution was stored at -20°C.
Cell culture
U87, LN229 and U251HF were obtained from the
Department of Neuro-Oncology, University of Texas M. D.
Anderson Cancer Center.  LN229 has wild-type PTEN and a
p53 gene mutation, while U87 has wild-type p53 with a PTEN
mutation [25].  U251HF has the p53 gene mutation and a
PTEN gene deletion [26].  All cell lines were cultured in
DMEM/F12 medium supplemented with 5% calf serum,
penicillin (100 U/ml), and streptomycin (100 µg/ml) and
incubated in a humidified atmosphere containing 5% CO2 at
37°C.
Cell proliferation assay
To assay cell viability after doxycycline treatment, we
conducted the MTT assay as described previously [27].
Briefly, 2000 cells/well were seeded in 96-well plates and
allowed to adhere after overnight culture.  The cells were
then treated with various concentrations of doxycycline for
24, 48 and 72 h in quadruplicate.  The media was decanted,
100 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) in DMEM/F12 medium (1 mg/ml) was added to
each well, and cells were incubated at 37°C for 1 h.
Formazan crystals in the wells were solubilized in 100 µl of
DMSO by shaking at room temperature for 1 h.  Absorbance
was measured at a wavelength of 570 nm by a
spectrophotometer.  The assay was repeated in 4-5
independent experiment replications.  In each replication,
the MTT values of treatment groups for each day were
normalized to, and expressed as percents of, the mean MTT
values of untreated cells at day 1.
Gelatinase zymography
To determine the effects of doxycycline on the activity of
secreted gelatinase from the glioma cells, quadruplicate sets
of cells (1 × 105) were seeded in 24-well plates, allowed to
attach, then treated with doxycycline at 5, 10 and 15 µg/ml
for 48 h under serum-free conditions.  The conditioned
media were collected from glioma cells after they had been
treated with doxycycline for 48 h.  We felt that conditioned
media obtained from continuous incubation with the drug
closely reflected what happened in the clinical setting as
patients were treated with doxycycline once to twice daily to
maintain a steady level of drug concentration.  Conditioned
media secreted from one set of glioma cells were collected,
and RNA was extracted from the same cells for analysis of
gene expression.  MTT assays were performed on the
remaining three sets of glioma cells as described above but
with triplicate amounts of reagents.
We followed the gelatinase zymography method described
previously [28].  Briefly 1-10 µl of each conditioned medium
was loaded into a 10% SDS-polyacrylamide gel containing
0.1% gelatin with a layer of stacking gel.  Proteins were
fractioned by electrophoresis at 100 volts for 90 min.  The
gel was washed by 0.25% Triton X-100 for 30 min, then
incubated in protease reactivation buffer [50 mM Tris-HCl
(pH 7.5), 150 mM NaCl and 10 mM CaCl2] for 16 h at 37°C with
gentle horizontal shaking.  Gelatinase activities were
visualized as clear bands after the gel was stained with 0.1%
Coomassie blue in 10% acetic acid and 10% isopropanol
followed by de-staining with 10% acetic acid and 30%
methanol.  The band sizes were determined by parallel
loading of a protein marker.  After wrapping the gel in a
cellophane sheet and allowing it to dry in air, the bands were
quantified using ChemiImager 5500 and Alpha Ease FC
software (Alpha Innotech Corp, San Leandro, CA, USA).  The
assay was repeated using materials from three independent
experiment replications with 3 repeats per treatment.  To
adjust for doxycycline dose effects on cell proliferation,
MMP2 activities from each treatment group were converted
into ratios relative to the mean MTT value for that treatment
group.  To normalize the different replications to a common
reference, the MMP2/MTT ratios were expressed as
percentages of the mean of the no-treatment control prior to
statistical analysis.
RNA isolation, cDNA synthesis, and real-time quantitative
RT-PCR (QRT-PCR)
RNA was extracted from cell cultures using Ultraspec
(Biotecx Laboratories, Houston, TX, USA) following the
manufacturer’s protocol and converted to cDNA by
SuperScript reverse transcriptase II (Invitrogen, Carlsbad,
CA, USA) with a poly-d(T) primer as described previously
[29].  Gene expressions were quantified using a Light Cycle
(LC) instrument and LC Faststart DNA Master SYBR Green I
enzyme mix (Roche, Indianapolis, IN, USA) with primers and
gene-specific standards for GAPDH, enolase-α, and MMP2
as described previously [29].  The real time QRT-PCR of each
cDNA sample was repeated in two individual runs, and the
data from two separate experiments was taken for statistical
analysis.
In vitro invasion assay
The Matrigel Basement Membrane Matrix (Becton Dickson
Labware, Bedford, MA, USA) was used to perform the in vitro
cell invasion assays.  U251HF cells (1.0 × 105 in 0.7 ml
DMEM/F12 with and without 5 or 10 µg/ml of doxycycline)
were seeded in the upper chamber of a Costar Transwell (12-
mm diameter, 12-µm pore size), which was coated with 200 µl
of Matrigel (1 mg/ml).  Medium (1 ml) supplemented with
0.05% calf serum was added to the lower compartment of the
chamber to provide chemo-attractants.  After incubation for
16 h, the cells that had invaded through the Matrigel and
migrated to the lower surface of the filter were fixed and
stained using a HEMA3 staining kit (Fisher Scientific,
Houston, TX, USA).  A total of ten pictures of randomly
picked microscope fields at 200× magnification were taken
for each filter, and cell numbers were counted.  Each
experiment was performed in triplicate and repeated twice.
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Figure 1: Determination of the effect of
doxycycline on glioma cell growth by MTT
assay, showing the growth of U251HF, U87 and
LN229 glioma cells in the presence of various
concentrations of doxycycline in medium
supplemented with 5% calf serum (CS)(A-C,
respectively) or in serum-free (SF) medium (D-F,
respectively).  Cell viabilities of the treatment
groups were normalized to the mean MTT values
of untreated cells at Day 1 (assigned as 100%)
for each cell line.  The data represent mean ± SD
of 12-15 repeats from 4-5 independent experi-
ments from the Least-Square Means (LS Means)
and ANOVA SD analyzed via mixed-models
ANOVA.
Statistical Analysis
Mixed-model ANOVAs, with either Bonferroni's or
Dunnett's procedures for the post hoc comparisons, were
used to examine the statistical differences between groups
in the cell proliferation assays, gelatinase zymography, and
real-time QRT-PCR of MMP2 expression.  Matrigel cell
counts were analyzed via Poisson regression, with
generalized estimating equations to model the correlation
between different microscope fields of view from the same
culture and with cell counts normalized to the percent of
control by means of the offset variable.  The statistical
significance was set at P < 0.05.
Results
Doxycycline affects glioma cell proliferation
Though there have been reports of doxycycline’s
cytotoxic effects in multiple tumor cell lines, no studies have
been done using malignant glioma cell lines.  We studied the
effect of doxycycline on glioma cell proliferation by exposing
U251HF, U87, and LN229 cells to increasing concentrations
of doxycycline (5, 10, 15, 20, 25, 30 and 35 µg/ml) for 1, 2, and
3 days in DMEM/F12 medium containing 0 or 5% serum.  Cell
viability was determined by MTT assay.  Comparison of
treated cells to untreated control cells at Day 1 revealed that
doxycycline had no significant immediate effect on cell
viability when applied at low concentrations (5-15 µg/ml) to
all three glioma cell lines in the presence or absence of
serum (P > 0.05, Figure 1 and Table 1).  Moderate supp-
ression from doxycycline at higher concentrations (20-35
µg/ml) in serum-free conditions was observed at Day 1 in
U251HF and LN229 cells (P < 0.05), with a similar trend
shown by U87 cells (P = 0.06).
In culture conditions supplemented with 5% calf serum, a
concentration-dependent growth-inhibitory effect was
observed in all three glioma cell lines starting from Day 2
after treatment, as shown by the trend of change on cell
viability (Figure 1).  Significant P values were observed at
Days 2 and 3 when comparing high concentration groups
with the untreated control, while comparison of low con-
centration groups with the control revealed no significant P
value (Table 1).  When a low concentration of doxycycline
was used, cells continued to proliferate for 2 days, as shown
by the comparison of Day 2 to Day 1 (P < 0.0001 or less).
Although there was a trend for MTT values to increase from
Day 2 to Day 3 under low concentration conditions, the P
values were not significant (Table 1), including comparison
with no-treatment controls.  This suggests that cell
proliferation slowed considerably by Day 3 in this assay
condition.  Thus there was a growth-inhibitory but not a
cytotoxic effect from doxycycline on all three glioma cell
lines treated in medium containing serum.
Under serum-free culture conditions, cells that were
exposed to low concentrations of doxycycline displayed a
similar behavior to those cultured in 5% serum, as shown by
similar P values in Table 1.  However, viability of U87 and
LN229 cells tended to be reduced in response to high
concentrations of doxycycline treatments.  A similar, but
less obvious trend was observed with lower concentrations
as well (Figure 1E and 1F).  For example, the cell viability of
U87 cells at Day 3 was reduced to 79% compared to that at
Day 2 in the high concentration group (P < 0.05), indicating a
cytotoxic effect of doxycycline on U87 cells in serum-free
conditions.  In U251HF cells, the curve for cell viability was
essentially the same between Day 2 and Day 3 for all
treatment groups including the untreated control cells
(Figure 1D).  Thus in serum-free condition, U251HF cells
were more resistant to the cytotoxic effect of doxycycline
than U87 and LN229 cells.  Based on these observations, we
chose 2 days as the treatment duration for the zymography
and invasion studies, and normalized zymography data by
MTT value of the cells.
Effect of doxycycline on the MMP2 activity of glioma cell
lines
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Table 1: Bonferroni P values for comparisons of cell viability among grouped high or low concentrations of doxycycline treatment per cell line
and medium
       U251HF___            U87_____          LN229____Comparison
5% serum Serum free 5% serum Serum free 5% serum Serum free
Day 1 Low dose1 vs. Ctrl2 1.0000 1.0000 1.0000 1.0000 0.4146 1.0000
Day 2 Low dose vs. Ctrl 0.2081 1.0000 1.0000 1.0000 1.0000 1.0000
Day 3 Low dose vs. Ctrl 0.0378 1.0000 0.0694 0.3269 0.1658 0.3464
Low dose Day 2 vs. Day 1 < .0001 0.0007 < .0001 < .0001 < .0001 < .0001
Low dose Day 3 vs. Day 2 1.0000 1.0000 1.0000 1.0000 1.0000 0.4941
Day 1 High dose3 vs. Ctrl 0.0243 0.0010 0.5625 0.0622 1.0000 0.0325
Day 2 High dose vs. Ctrl < .0001 < .0001 < .0001 0.0026 < .0001 0.0201
Day 3 High dose vs. Ctrl < .0001 < .0001 < .0001 < .0001 < .0001 0.0028
High dose Day 2 vs. Day 1 0.6062 0.0088 < .0001 < .0001 0.0003 < .0001
High dose Day 3 vs. Day 2 1.0000 1.0000 1.0000 0.0373 1.0000 1.0000
15-15 µg/ml doxycycline; 2control, no doxycycline; 320-35 µg/ml doxycycline.
Figure 2: Determination of the effect of doxycycline on MMP2
activity of glioma cells by zymography assay.  A, Representative
zymography gels for U251HF and U87 cells after treatment with
doxycycline (5, 10, and 15 µg/ml) for 48 h.  B, Normalized extra-
cellular active MMP2 levels of U251HF and U87 cells after
doxycycline treatment.  The data represent mean ± SD of 9 repeats
from 3 independent experiments from the LSMeans and ANOVA SD
analyzed via mixed-models ANOVA.  Horizontal lines above bars
indicate treatment groupings, with Dunnett-adjusted P values for
comparisons to the untreated grouping.
MMP2 and MMP9 are two proteinases responsible for
degradation of extracellular matrix that is necessary for GBM
tumor invasion [5].  MMP2 activities were easily detected in
both U87 and U251HF cells, but MMP9 activity was too low to
be detected in either cell line.  In Figure 2A, representative
zymography gels of U251HF and U87 cells following
doxycycline treatment are shown.  Decreased MMP2 activity
was observed as the concentration of doxycycline increased
(5, 10 and 15 µg/ml) in U251HF cells, while no change or
slightly increased MMP2 activity was observed in U87 cells.
Cell viability studies from the same experiments showed
more inhibition of cell viability in U87 cells than U251HF cells
(data not shown), consistent with results based on cells
treated in 96-well plates (Figure 1D and 1E).
Because of the occurrence of cytotoxic effects of
doxycycline in U87 cells, we normalized quantified MMP2
activity to the mean of the MTT values of cells in paralleled
groups.  As shown in Figure 2B, the extracellular active
MMP2 level of U251HF cells was decreased by exposure to
low concentrations of doxycycline (5, 10 and 15 µg/ml) to
84.4%, 88.3%, and 84.5%, respectively (ANOVA pooled SD =
9.9%; P < 0.05 in all three cases).  However, doxycycline
unexpectedly increased MMP2 activity of U87 cells by
126.5%, 124.5%, and 124.2%, respectively, after the same
treatment (ANOVA pooled SD = 13.6%; P < 0.01 in all three
cases), a result in accordance with an increase in MMP2
expression as described below.
Effect of doxycycline on regulation of MMP2 gene trans-
cription in glioma cell lines
To determine if doxycycline regulates MMP2 at the level of
transcription, real-time QRT-PCR for MMP2, enolase-α and
GAPDH were performed on cDNA extracted from U25HF and
U87 glioma cells with and without exposure to doxycycline.
As shown in Figure 3A, the levels of MMP2 gene expression
were normalized to either enolase-α or GAPDH in U251HF
cells.  Treatment with low concentrations of doxycycline did
not change MMP2 expression levels from that from the
control group (P > 0.05 after both pairwise comparison and
linear trend analysis).
For U87 cells, however, the trend with increasing
concentrations of doxycycline is statistically significant
whether normalized to enolase-α or to GAPDH (Figure 3B).
Pairwise comparisons to 0 µg/ml were not so significant
once the results were adjusted for the multiple comparisons,
but the test for trend was significant (P = 0.012 for
MMP2/enolase-a; P = 0.020 for MMP2/GAPDH), indicating
that doxycycline has an enhancing effect on MMP2
transcription in U87 cells.
Effect of doxycycline on glioma cell invasion
Since MMP2 is a proinvasive protein, the doxycycline-
mediated reduction of extracellular active MMP2 levels in
U251HF cells would be expected to result in decreased cell
invasiveness.  The Matrigel invasion assay was performed to
confirm this hypothesis.  As shown in Figure 4, treatment
with doxycycline brought about a concentration-dependent
decrease in the number of cells that invaded through the
filter following treatment with doxycycline.  U251HF cells
exposed to doxycycline at 5 µg/ml and 10 µg/ml showed
respective reductions (95% confidence intervals) of 24.8%
(12.6%-35.3%) and 43.4% (30.4%-53.9%) compared to
untreated  control  cells  (P < 0.001 in both cases).   Thus  the
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Figure 3: Determination of the effect of doxycycline on MMP2
expression in glioma cells by real-time QRT-PCR.  The level of
MMP2 expression in (A) U251HF and (B) U87 cells 48 h after treat-
ment with doxycycline at various concentrations was normalized
to enolase-a and GAPDH expression, and was expressed as
percent of zero-concentration control in each of two replicate
experiments, then log-transformed to stabilize variance for
analysis via mixed-models ANOVA.  The data represent mean ± SD,
which were calculated by back-transformation from ANOVA
results.  Post-hoc contrasts for linear trend with concentration
yielded the following results for U251HF cells: F = 2.13, DFs = (1,
3), P = 0.24 for MMP2/enolase-a, and F = 0.87, DFs = (1, 3), P = 0.42
for MMP2/GAPDH.  For U87 cells: F = 12.49, DFs = (1, 6), P = 0.012
for MMP2/enolase-a, and F = 9.89, DFs = (1, 6), P = 0.020 for
MMP2/GAPDH.
reduction of MMP2 activity by doxycycline in U251HF cells
was correlated with reduction of the cell invasiveness.
Discussion
Doxycycline belongs to the tetracycline family of drugs,
members of which function as anti-microbial agents by
preventing the binding of aminoacyl tRNA to the ribosome,
thereby inhibiting protein synthesis [30].  It has been known
for years that members of the tetracycline family, such as
doxycycline and minocycline, inhibit the growth of various
tumor cells in vitro [31].  Doxycycline was found to be the
most effective analogue of tetracycline at inhibiting cell
survival in a human adenocarcinoma cell line [21].  The
mechanisms for doxycycline anti-proliferative effects have
been reported, and include impairment of mitochondrial
protein synthesis [10,11], proliferation arrest in the G1 phase
of cell cycle [32],  and  induction  of  apoptosis  by caspase-3
Figure 4: Determination of the effect of doxycycline on the
invasiveness of U251HF cells by Matrigel invasion assay.  The
position of the bar is the mean of the normalized cell counts from
triplicate invasion assays of 2 independent experiments.  Matrigel
cell counts were analyzed via Poisson Regression with
Generalized Estimating Equation (GEE) methodology to model the
correlation among different microscope fields of view from the
same culture.  Cell counts were normalized to the percent of the
control by means of the offset variable.
activation in human T-lymphoblastic leukemia cells [33].
However, the serum concentrations of doxycycline required
to achieve these cytotoxic effects are generally higher (20 to
50 µg/ml) than the typical therapeutic serum concentration
used to treat infections, generally from 0 to 5 µg/ml and
occasionally as high as 10 µg/ml [22], making doxycycline
less desirable as a cytotoxic agent.
There are reports showing that different cancer cell lines
have different sensitivities to doxycycline.  Doxycycline at 10
µg/ml was sufficient to induce G0/G1 arrest, and a con-
centration of 20 µg/ml was able to provoke mitochondrion-
mediated apoptosis in HT 29 cells [17,34].  In prostate cancer
cell culture, necrosis and apoptosis were not apparent until
doxycycline concentrations exceeded 20 µg/ml [13].  In our
study, when three glioma cell lines were cultured in 5%
serum, the anti-proliferative effects of doxycycline were also
observed only following high-concentration treatments (20,
25, 30, and 35 µg/ml).  In clinical settings, GBM is highly
resistant to cytotoxic intervention as compared to other
solid tumors, and this may be a clinical reflection of our
observation that glioma cells require higher concentrations
of doxycycline in vitro to achieve its effect on growth
inhibition.
We also investigated the anti-proliferative effects of
doxycycline when cells were exposed to serum-free
conditions in an attempt to avoid the effects of various
growth hormones and cytokines in the serum that may not
exist around the tumor bed due to brain-blood barrier.  We
chose 24-48 h as the length of the treatment and serum-free
medium as the culture condition to investigate any effect of
doxycycline on cell proliferation, MMP2 activity and cell
invasion.  In this study, we applied a new concept, termed
normalized MMP2 activity (MMP2 activity/MTT value) in order
to minimize confounding by the anti-proliferative effect from
doxycycline on the measurement of extracellular active
MMP2 level in the treatment group.
Our data revealed two different responses to doxycycline
in two glioma cell lines.  In the U251HF cell line, cell
proliferation was not altered while the extracellular active
MMP2 level was decreased with low-concentration doxy-
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cycline treatment (5, 10, and 15 µg/ml).  By real-time QRT-
PCR, we demonstrated unchanged MMP2 mRNA levels in
response to doxycycline treatments, which suggested that
the effects of doxycycline on MMP2 were at the post-
translational level.  This is consistent with a known
mechanism, that doxycycline inhibits MMP2 through
chelation of the zinc ion at the active site of the enzyme [21],
rather than at the level of mRNA by reducing MMP2 mRNA
stability as reported in one study [24].  Interestingly, there
was a 20% decrease in normalized MMP2 activity by a low-
concentration doxycycline treatment (5 µg/ml), and the effect
of inhibition was not strengthened upon increasing the
concentration.  This suggests that 5 µg/ml of doxycycline
has reached to the maximal inhibition on MMP2 activity in
U251HF cells.  Conversely, in U87 cells, low-concentration
doxycycline slightly inhibited cell proliferation while
enhanced extracellular MMP2 activity.  One possible
explanation is that mild cytotoxic effects exerted by low-
concentration doxycycline in U87 cells triggered cellular
stress response which activated MMP2 gene transcription,
as shown by real-time QRT-PCR.  Although not directly
observed, there was a concentration-dependent inhibition on
MMP2 activity in U87 by doxycycline which masked a
concentration-dependent increase of MMP2 secretion.  The
different responses toward doxycycline in the above two cell
lines are striking, which may be related to their genetic
difference.  A wild-type p53 phenotype may render U87 cells
more susceptible to cytotoxic agents than the more
aggressive U251HF cell line which has a mutated p53
phenotype.
Emerging evidence suggests a balance between glioma
cell migration/invasion and proliferation [35].  Biopsies
obtained from glioma specimens and their migratory tracts
have demonstrated that highly invasive glioma cells have a
slower proliferation rate [36], which renders the invasive
glioma cell phenotype relatively resistant to cytotoxic
interventions, such as radiation and chemotherapy.  It has
been reported that the integrin signal transduction pathways
are often shared by cell invasion, proliferation and survival
[37].  Our study in U251HF and U87 cells provides a good
model for further exploration of the regulation mechanism
behind the balance between migration/invasion and
proliferation.  Such a model will enable us to have a better
rationale in designing clinical trials with MMP inhibitors and
cytotoxic agents.
Our observation of doxycycline’s effect in U251HF cells on
cell invasion is comparable to data published in the current
literature.  Doxycycline at 6 µg/ml inhibited osteosarcoma
cell invasion by 28.8% [38].  Doxycycline at 5 µg/ml reduced
active and latent forms of MMP2 secreted from cultured
abdominal aorta aneurysm tissue by 50% and 30%, and
cultured smooth muscle cells by 37% [24], suggesting that
doxycycline may be a promising anti-aneurysm and anti-
atherosclerotic plaque agent for clinical trials [39,40].
Doxycycline is a non-specific MMP inhibitor.  Although we
were unable to examine the effect of doxycycline on MMP9
due to relatively low MMP9 activities in all three glioma cell
cultures, it has been reported that doxycycline inhibits TGF-
β1-induced MMP9 via the Smad and MAPK pathways in
human corneal epithelial cells [41].
The complexity of the MMP family makes studying MMP
inhibitors challenging.  MMPs have multiple signaling
pathways which might serve as targets for anticancer
intervention; however, the inhibition of some MMPs could
potentially have pro-tumorigenic effect [42].  So far, two main
classes of MMP inhibitors have been investigated.  One
class represents a family of small molecules that bind to the
enzymatic site.  Members in the other class are
pseudopeptides that act as competitive inhibitors for MMPs
[44].  With emerging evidence suggesting that tetracycline
family members can function as MMP inhibitors, there is a
renewed interest in studying tetracycline analogues, such as
doxycycline, minocycline, and especially non-antimicrobial
tetracycline analogs.  Application of the anti-MMP properties
of tetracycline family members has extended into multiple
medical fields, such as neurological disease, inflammatory
diseases and tumor metastasis [9].
MMP2 has been validated as an anticancer drug target in
some aggressive tumor types [42].  Our study is the first to
show that doxycycline in acceptable therapeutic concen-
trations functions as a MMP2 inhibitor of glioma cells, and
this is manifested by a decrease in MMP2 activity.
Interestingly, doxycycline inhibits U251HF cell migration and
invasion in a concentration-dependent fashion which
suggests that mechanisms other than a simple decrease in
MMP activity are involved.  It has been reported that doxy-
cycline exerts an anti-angiogenesis effect independent of
being an MMP inhibitor [44].
Doxycycline has a long track record as being a safe drug,
and it is the only FDA approved MMP inhibitor for the
treatment of periodontitis [8].  Our study revealed that
doxycycline at the clinical therapeutic level can decrease
MMP2 activity at the post-translational level, and moreover
can hinder invasion by one of the most aggressive glioma
cell lines.  However, in U87 cells, the cytotoxic effects of
doxycycline may trigger MMP2 expression indirectly, and
this warrants further investigation.  With the drug’s long and
safe history doxycycline clearly deserves more attention as
a therapeutic intervention in GBM, especially considering
that few efficacious agents are currently available.
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